Global Injectable Drug Delivery Market (2010 - 2015)
KEY TAKE AWAYS
MARKETS COVERED
Rapid enhancements in drug discovery technologies leading to developments in proteomics and genomics have essentially had a greater impact on injectable drug delivery market. The number of injectable drugs to be introduced in medium to long term future is expected to be significant, to outweigh the threat from advanced alternative drug delivery technologies. Additionally increasing innovation in alternative technologies has extended the focus of injectable market participants on issues such injector design, convenience and painless modes of injectables and customization. The aligned pharmaceutical industries are actively collaborating with drug delivery companies to effectively target the patient concerns. Such strategic issues are driving the market significantly. The changing market trends, compels the industry participants to have extended clarity on market dynamics, increasing innovation from alternative technologies and threat from competitors in injectable drug delivery market to sustain their market position.
This report highlights the global injectable drug delivery market segmented as below
Our analysis would enable the industry players to get acquainted with the upcoming trends, opportunities and challenges in the market along with a detailed analysis of the sub-markets as well. The report will size all the sub markets and also give a detailed geographic split among the four major markets of North America, Europe, Asia and Rest of the World. We will provide market trends and forecasts supported by the drivers and inhibitors for each sub-segment. More than 100 market tables and top company profiles will provide a deeper insight into the market and the competitive landscape as well. We will categorize market tables into geographic regions, products, applications and bio-feed stocks.
In addition to the market size, data trends and forecasts, the report will also highlight key opportunity areas for the relevant stakeholders. We will analyze new product launches. In addition, we will analyze and profile key market developments of the top companies in this market and its sub-segments while drawing a competitive landscape for major markets and their sub segments.
- To define and measure the Injectable drug delivery market and its various sub-segments with respect to types of systems, by mode of drug delivery, by therapeutics, by re-usability and by drugs delivered
- To identify the major drivers and restraints of the market
- To identify and analyze comprehensively the market structure with respect to the factors influencing the market growth and industry specific challenges.
- To analyze the trends and forecasts of the injectable drug delivery market and its segments
- To identify the major stakeholders in the market and draw a competitive landscape for the market leaders
- To analyze the opportunities in the market for the stakeholders
- To strategically analyze micro markets with respect to their individual growth trends, future prospects and contribution to the total market
- To understand the regulatory framework, design criteria, pricing issues, threat from alternative methods available in the market.
- To analyze and forecast the revenues of market segments with respect to geographies (North America, Europe, Asia and Rest of the World
- To provide comprehensive analysis of the Top players in Injectable drug delivery market competitive scenario.
MARKETS COVERED
Rapid enhancements in drug discovery technologies leading to developments in proteomics and genomics have essentially had a greater impact on injectable drug delivery market. The number of injectable drugs to be introduced in medium to long term future is expected to be significant, to outweigh the threat from advanced alternative drug delivery technologies. Additionally increasing innovation in alternative technologies has extended the focus of injectable market participants on issues such injector design, convenience and painless modes of injectables and customization. The aligned pharmaceutical industries are actively collaborating with drug delivery companies to effectively target the patient concerns. Such strategic issues are driving the market significantly. The changing market trends, compels the industry participants to have extended clarity on market dynamics, increasing innovation from alternative technologies and threat from competitors in injectable drug delivery market to sustain their market position.
This report highlights the global injectable drug delivery market segmented as below
- Injectable systems (Sustained Release Injectable Systems, Needleless Systems Microneedle Injectors, Liposomal Systems/ PEGylation, Novel Injectable Technologies)
- By mode of drug delivery (Intradermal, Subcutaneous, Intramuscular, Intravenous, Intraosseous, intraperitoneal)
- By Therapeutics (Diabetes, Hepatitis C, Oncology, Rheumatoid Arthritis etc)
- By Reusability (Reusable, Disposable, Pre-filled, Custom)
- By Drug Classes (Antimuscarinics, Cytokines, Dopamine, Hematopoietics, Human Growth Hormone etc)
Our analysis would enable the industry players to get acquainted with the upcoming trends, opportunities and challenges in the market along with a detailed analysis of the sub-markets as well. The report will size all the sub markets and also give a detailed geographic split among the four major markets of North America, Europe, Asia and Rest of the World. We will provide market trends and forecasts supported by the drivers and inhibitors for each sub-segment. More than 100 market tables and top company profiles will provide a deeper insight into the market and the competitive landscape as well. We will categorize market tables into geographic regions, products, applications and bio-feed stocks.
In addition to the market size, data trends and forecasts, the report will also highlight key opportunity areas for the relevant stakeholders. We will analyze new product launches. In addition, we will analyze and profile key market developments of the top companies in this market and its sub-segments while drawing a competitive landscape for major markets and their sub segments.
EXECUTIVE SUMMARY
OBJECTIVE
MARKET SCENARIO
1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
2 SUMMARY
3 MARKET OVERVIEW
3.1 INJECTABLE DRUG DELIVERY MARKET
3.2 BIOLOGICS TO DRIVE GROWTH OF INJECTABLES
3.3 SELF-ADMINISTRATION TRENDS SHAPING THE INJECTABLE DRUG DELIVERY MARKET
3.4 PRODUCT LIFE CYCLE MANAGEMENT THROUGH DRUG DELIVERY
3.5 DEVELOPMENT OF SMART INJECTION DEVICES
3.6 KEY MARKET DYNAMICS
3.6.1 DRIVERS
3.6.1.1 Favored for delivery of biological drugs & gene therapy
3.6.1.2 Growth in the prefilled syringes and autoinjectors market
3.6.1.3 Product life cycle management
3.6.1.4 Improving patient compliance
3.6.2 RESTRAINTS
3.6.2.1 Fear of needles
3.6.2.2 Issues with self-administration
3.6.2.3 Threat from alternate delivery methods
3.6.3 OPPORTUNITIES
3.6.3.1 Microneedles and needle free systems
3.6.3.2 Biosimilars approval paves the way for growth of injectables
3.7 WINNING IMPERATIVES
3.7.1 ALLIANCES
3.7.2 SHIFT FROM PURE DRUG DELIVERY TOWARDS SPECIALTY PHARMACEUTICALS
3.8 MARKET SHARE OF KEY PLAYERS
4 MARKET BY DRUG DELIVERY DEVICES TECHNOLOGY
4.1 INJECTION DEVICES
4.1.1 KEY MARKET DYNAMICS
4.1.1.1 Drivers
4.1.1.1.1 Growth of self-administration therapies
4.1.1.1.2 Needle-stick legislations
4.1.1.1.3 Increasing acceptance by physicians and patients
4.1.1.1.4 Reducing cost of treatment
4.1.1.2 Restraints
4.1.1.2.1 Need for new drug formulation
4.1.1.3 Opportunities
4.1.1.3.1 Product differentiation through added functional features
4.1.1.3.2 Expansion to new areas
4.2 CRITERIA FOR SELECTION OF INJECTABLE DEVICE
4.3 KEY DEVELOPMENTS
4.3.1 DEVELOPMENT OF MICRONEEDLES
4.3.2 DEVELOPMENT OF NEEDLE-FREE DEVICES FOR ADMINISTRATION OF POWDERED DRUGS
4.4 CONVENTIONAL INJECTABLES
4.5 PREFILLED SYRINGES (PFS)
4.5.1 KEY MARKET DYNAMICS
4.5.1.1 Drivers
4.5.1.1.1 Growing market for self-injectable devices
4.5.1.1.2 Wastage control and cost reduction
4.5.1.1.3 Ease of manufacture and user friendly
4.5.1.2 Restraints
4.5.1.2.1 Threat from needle-free devices
4.5.1.2.2 Protecting product quality
4.5.2 GLASS PFS
4.5.3 PLASTIC PFS
4.6 SELF INJECTION DEVICES
4.6.1 AUTO INJECTORS
4.6.1.1 Reusable auto-injectors
4.6.1.2 Disposable auto-injectors
4.6.2 PEN INJECTORS
4.6.2.1 Reusable pen injectors
4.6.2.2 Disposable pen injectors
4.6.3 NEEDLE-FREE INJECTORS (NFI)
4.6.3.1 Reusable NFIs
4.6.3.2 Disposable NFIs
4.7 OTHERS
5 DRUG DELIVERY FORMULATION TECHNOLOGIES
5.1 INTRODUCTION
5.2 KEY MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing government funding for nanotechnology
5.2.1.2 Improved solubility of poorly water soluble drugs
5.2.1.3 Targeted drug delivery through nano-systems
5.2.1.4 Increasing acceptance in treatment of chronic diseases
5.2.2 RESTRAINTS
5.2.2.1 Difficulty in commercialization
5.2.2.2 Safety issues
5.2.2.3 Lack of regulations
5.2.3 OPPORTUNITIES
5.2.3.1 Symbiotic partnership with pharma companies
5.3 KEY DEVELOPMENTS
5.3.1 DENDRIMER TECHNOLOGY
5.3.2 NANOSPONGE
5.3.3 RNAI BASED DRUG DELIVERY PLATFORM
5.4 LIPOSOMAL SYSTEMS
5.5 MICROSPHERES
5.6 POLYMERIC MICELLES
5.7 BIODEGRADABLE POLYMERS
5.8 OTHERS
6 MARKET BY THERAPEUTICS
6.1 INTRODUCTION
6.2 MULTIPLE SCLEROSIS
6.3 OSTEOPOROSIS
6.4 PAIN MANAGEMENT
6.5 DIABETES
6.6 ONCOLOGY
6.7 RHEUMATOID ARTHRITIS
6.8 ANEMIA
6.9 HEPATITIS C
6.1 CROHN'S DISEASE
6.11 PSORIASIS
6.12 OTHERS
7 COMPETITIVE LANDSCAPE
7.1 KEY DEVELOPMENTS
7.1.1 AGREEMENTS & PARTNERSHIPS
7.1.2 NEW PRODUCT LAUNCH
7.1.3 EXPANSION
7.1.4 REGULATORY APPROVAL
7.1.5 MERGERS & ACQUISITIONS
8 COMPANY PROFILES
8.1 BAXTER BIOPHARMA SOLUTIONS
8.1.1 OVERVIEW
8.1.2 FINANCIALS
8.1.3 PRODUCTS & SERVICES
8.1.4 STRATEGY
8.1.5 DEVELOPMENTS
8.2 BECTON, DICKINSON AND COMPANY
8.2.1 OVERVIEW
8.2.2 FINANCIALS
8.2.3 PRODUCT & SERVICES
8.2.4 STRATEGY
8.2.5 DEVELOPMENTS
8.3 SCHOTT AG
8.3.1 OVERVIEW
8.3.2 FINANCIALS
8.3.3 PRODUCT AND SERVICES
8.3.4 STRATEGY
8.3.5 DEVELOPMENTS
8.4 SURMODICS, INC.
8.4.1 OVERVIEW
8.4.2 PRODUCTS AND SERVICES
8.4.3 FINANCIALS
8.4.4 STRATEGY
8.4.5 DEVELOPMENTS
8.5 GERRESHEIMER AG
8.5.1 OVERVIEW
8.5.2 PRODUCTS & SERVICES
8.5.3 FINANCIALS
8.5.4 STRATEGY
8.5.5 DEVELOPMENTS
8.6 CROSSJECT
8.6.1 OVERVIEW
8.6.2 PRODUCT & SERVICES
8.6.3 STRATEGY
8.6.4 DEVELOPMENTS
8.7 CYDEX PHARMACEUTICALS, INC.
8.7.1 OVERVIEW
8.7.2 PRODUCT & SERVICES
8.7.3 STRATEGY
8.7.4 DEVELOPMENTS
8.8 NORWOOD ABBEY LTD.
8.8.1 OVERVIEW
8.8.2 PRODUCT & SERVICES
8.8.3 STRATEGY
8.8.4 DEVELOPMENTS
8.9 PACIRA PHARMACEUTICALS, INC.
8.9.1 OVERVIEW
8.9.2 PRODUCT & SERVICES
8.9.3 STRATEGY
8.9.4 DEVELOPMENTS
8.1 VETTER PHARMA-FERTIGUNG GMBH & CO. KG
8.10.1 OVERVIEW
8.10.2 PRODUCT & SERVICES
8.10.3 STRATEGY
8.10.4 DEVELOPMENTS
8.11 B. BRAUN MELSUNGEN AG
8.11.1 OVERVIEW
8.11.2 PRODUCT & SERVICES
8.11.3 FINANCIALS
8.11.4 STRATEGY
8.11.5 DEVELOPMENTS
8.12 ZOGENIX, INC.
8.12.1 OVERVIEW
8.12.2 PRODUCTS & SERVICES
8.12.3 STRATEGY
8.12.4 DEVELOPMENTS
8.13 TERUMO CORPORATION
8.13.1 OVERVIEW
8.13.2 PRODUCTS & SERVICES
8.13.3 FINANCIALS
8.13.4 STRATEGY
8.13.5 DEVELOPMENTS
8.14 SHL GROUP
8.14.1 OVERVIEW
8.14.2 PRODUCTS & SERVICES
8.14.3 STRATEGY
8.14.4 DEVELOPMENTS
8.15 AP PHARMA, INC.
8.15.1 OVERVIEW
8.15.2 PRODUCTS & SERVICES
8.15.3 FINANCIALS
8.15.4 STRATEGY
8.15.5 DEVELOPMENTS
8.16 BIOJECT, INC.
8.16.1 OVERVIEW
8.16.2 PRODUCTS & SERVICES
8.16.3 FINANCIALS
8.16.4 STRATEGY
8.16.5 DEVELOPMENTS
8.17 ALKERMES, INC.
8.17.1 OVERVIEW
8.17.2 PRODUCTS & SERVICES
8.17.3 FINANCIALS
8.17.4 STRATEGY
8.17.5 DEVELOPMENTS
8.18 WEST PHARMA SERVICES, INC.
8.18.1 OVERVIEW
8.18.2 PRODUCTS & SERVICES
8.18.3 FINANCIALS
8.18.4 STRATEGY
8.18.5 DEVELOPMENTS
8.19 OWEN MUMFORD LTD.
8.19.1 OVERVIEW
8.19.2 PRODUCTS & SERVICES
8.19.3 FINANCIALS
8.19.4 STRATEGY
8.19.5 DEVELOPMENTS
8.2 YPSOMED HOLDING AG
8.20.1 OVERVIEW
8.20.2 PRODUCTS & SERVICES
8.20.3 FINANCIALS
8.20.4 STRATEGY
8.20.5 DEVELOPMENTS
8.21 ANTARES PHARMA, INC.
8.21.1 OVERVIEW
8.21.2 PRODUCTS & SERVICES
8.21.3 FINANCIALS
8.21.4 STRATEGY
8.21.5 DEVELOPMENTS
8.22 QLT, INC.
8.22.1 OVERVIEW
8.22.2 PRODUCTS & SERVICES
8.22.3 FINANCIALS
8.22.4 STRATEGY
8.22.5 DEVELOPMENTS
8.23 NEKTAR THERAPEUTICS, LTD.
8.23.1 OVERVIEW
8.23.2 PRODUCTS & SERVICES
8.23.3 FINANCIALS
8.23.4 STRATEGY
8.23.5 DEVELOPMENTS
OBJECTIVE
MARKET SCENARIO
1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
2 SUMMARY
3 MARKET OVERVIEW
3.1 INJECTABLE DRUG DELIVERY MARKET
3.2 BIOLOGICS TO DRIVE GROWTH OF INJECTABLES
3.3 SELF-ADMINISTRATION TRENDS SHAPING THE INJECTABLE DRUG DELIVERY MARKET
3.4 PRODUCT LIFE CYCLE MANAGEMENT THROUGH DRUG DELIVERY
3.5 DEVELOPMENT OF SMART INJECTION DEVICES
3.6 KEY MARKET DYNAMICS
3.6.1 DRIVERS
3.6.1.1 Favored for delivery of biological drugs & gene therapy
3.6.1.2 Growth in the prefilled syringes and autoinjectors market
3.6.1.3 Product life cycle management
3.6.1.4 Improving patient compliance
3.6.2 RESTRAINTS
3.6.2.1 Fear of needles
3.6.2.2 Issues with self-administration
3.6.2.3 Threat from alternate delivery methods
3.6.3 OPPORTUNITIES
3.6.3.1 Microneedles and needle free systems
3.6.3.2 Biosimilars approval paves the way for growth of injectables
3.7 WINNING IMPERATIVES
3.7.1 ALLIANCES
3.7.2 SHIFT FROM PURE DRUG DELIVERY TOWARDS SPECIALTY PHARMACEUTICALS
3.8 MARKET SHARE OF KEY PLAYERS
4 MARKET BY DRUG DELIVERY DEVICES TECHNOLOGY
4.1 INJECTION DEVICES
4.1.1 KEY MARKET DYNAMICS
4.1.1.1 Drivers
4.1.1.1.1 Growth of self-administration therapies
4.1.1.1.2 Needle-stick legislations
4.1.1.1.3 Increasing acceptance by physicians and patients
4.1.1.1.4 Reducing cost of treatment
4.1.1.2 Restraints
4.1.1.2.1 Need for new drug formulation
4.1.1.3 Opportunities
4.1.1.3.1 Product differentiation through added functional features
4.1.1.3.2 Expansion to new areas
4.2 CRITERIA FOR SELECTION OF INJECTABLE DEVICE
4.3 KEY DEVELOPMENTS
4.3.1 DEVELOPMENT OF MICRONEEDLES
4.3.2 DEVELOPMENT OF NEEDLE-FREE DEVICES FOR ADMINISTRATION OF POWDERED DRUGS
4.4 CONVENTIONAL INJECTABLES
4.5 PREFILLED SYRINGES (PFS)
4.5.1 KEY MARKET DYNAMICS
4.5.1.1 Drivers
4.5.1.1.1 Growing market for self-injectable devices
4.5.1.1.2 Wastage control and cost reduction
4.5.1.1.3 Ease of manufacture and user friendly
4.5.1.2 Restraints
4.5.1.2.1 Threat from needle-free devices
4.5.1.2.2 Protecting product quality
4.5.2 GLASS PFS
4.5.3 PLASTIC PFS
4.6 SELF INJECTION DEVICES
4.6.1 AUTO INJECTORS
4.6.1.1 Reusable auto-injectors
4.6.1.2 Disposable auto-injectors
4.6.2 PEN INJECTORS
4.6.2.1 Reusable pen injectors
4.6.2.2 Disposable pen injectors
4.6.3 NEEDLE-FREE INJECTORS (NFI)
4.6.3.1 Reusable NFIs
4.6.3.2 Disposable NFIs
4.7 OTHERS
5 DRUG DELIVERY FORMULATION TECHNOLOGIES
5.1 INTRODUCTION
5.2 KEY MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing government funding for nanotechnology
5.2.1.2 Improved solubility of poorly water soluble drugs
5.2.1.3 Targeted drug delivery through nano-systems
5.2.1.4 Increasing acceptance in treatment of chronic diseases
5.2.2 RESTRAINTS
5.2.2.1 Difficulty in commercialization
5.2.2.2 Safety issues
5.2.2.3 Lack of regulations
5.2.3 OPPORTUNITIES
5.2.3.1 Symbiotic partnership with pharma companies
5.3 KEY DEVELOPMENTS
5.3.1 DENDRIMER TECHNOLOGY
5.3.2 NANOSPONGE
5.3.3 RNAI BASED DRUG DELIVERY PLATFORM
5.4 LIPOSOMAL SYSTEMS
5.5 MICROSPHERES
5.6 POLYMERIC MICELLES
5.7 BIODEGRADABLE POLYMERS
5.8 OTHERS
6 MARKET BY THERAPEUTICS
6.1 INTRODUCTION
6.2 MULTIPLE SCLEROSIS
6.3 OSTEOPOROSIS
6.4 PAIN MANAGEMENT
6.5 DIABETES
6.6 ONCOLOGY
6.7 RHEUMATOID ARTHRITIS
6.8 ANEMIA
6.9 HEPATITIS C
6.1 CROHN'S DISEASE
6.11 PSORIASIS
6.12 OTHERS
7 COMPETITIVE LANDSCAPE
7.1 KEY DEVELOPMENTS
7.1.1 AGREEMENTS & PARTNERSHIPS
7.1.2 NEW PRODUCT LAUNCH
7.1.3 EXPANSION
7.1.4 REGULATORY APPROVAL
7.1.5 MERGERS & ACQUISITIONS
8 COMPANY PROFILES
8.1 BAXTER BIOPHARMA SOLUTIONS
8.1.1 OVERVIEW
8.1.2 FINANCIALS
8.1.3 PRODUCTS & SERVICES
8.1.4 STRATEGY
8.1.5 DEVELOPMENTS
8.2 BECTON, DICKINSON AND COMPANY
8.2.1 OVERVIEW
8.2.2 FINANCIALS
8.2.3 PRODUCT & SERVICES
8.2.4 STRATEGY
8.2.5 DEVELOPMENTS
8.3 SCHOTT AG
8.3.1 OVERVIEW
8.3.2 FINANCIALS
8.3.3 PRODUCT AND SERVICES
8.3.4 STRATEGY
8.3.5 DEVELOPMENTS
8.4 SURMODICS, INC.
8.4.1 OVERVIEW
8.4.2 PRODUCTS AND SERVICES
8.4.3 FINANCIALS
8.4.4 STRATEGY
8.4.5 DEVELOPMENTS
8.5 GERRESHEIMER AG
8.5.1 OVERVIEW
8.5.2 PRODUCTS & SERVICES
8.5.3 FINANCIALS
8.5.4 STRATEGY
8.5.5 DEVELOPMENTS
8.6 CROSSJECT
8.6.1 OVERVIEW
8.6.2 PRODUCT & SERVICES
8.6.3 STRATEGY
8.6.4 DEVELOPMENTS
8.7 CYDEX PHARMACEUTICALS, INC.
8.7.1 OVERVIEW
8.7.2 PRODUCT & SERVICES
8.7.3 STRATEGY
8.7.4 DEVELOPMENTS
8.8 NORWOOD ABBEY LTD.
8.8.1 OVERVIEW
8.8.2 PRODUCT & SERVICES
8.8.3 STRATEGY
8.8.4 DEVELOPMENTS
8.9 PACIRA PHARMACEUTICALS, INC.
8.9.1 OVERVIEW
8.9.2 PRODUCT & SERVICES
8.9.3 STRATEGY
8.9.4 DEVELOPMENTS
8.1 VETTER PHARMA-FERTIGUNG GMBH & CO. KG
8.10.1 OVERVIEW
8.10.2 PRODUCT & SERVICES
8.10.3 STRATEGY
8.10.4 DEVELOPMENTS
8.11 B. BRAUN MELSUNGEN AG
8.11.1 OVERVIEW
8.11.2 PRODUCT & SERVICES
8.11.3 FINANCIALS
8.11.4 STRATEGY
8.11.5 DEVELOPMENTS
8.12 ZOGENIX, INC.
8.12.1 OVERVIEW
8.12.2 PRODUCTS & SERVICES
8.12.3 STRATEGY
8.12.4 DEVELOPMENTS
8.13 TERUMO CORPORATION
8.13.1 OVERVIEW
8.13.2 PRODUCTS & SERVICES
8.13.3 FINANCIALS
8.13.4 STRATEGY
8.13.5 DEVELOPMENTS
8.14 SHL GROUP
8.14.1 OVERVIEW
8.14.2 PRODUCTS & SERVICES
8.14.3 STRATEGY
8.14.4 DEVELOPMENTS
8.15 AP PHARMA, INC.
8.15.1 OVERVIEW
8.15.2 PRODUCTS & SERVICES
8.15.3 FINANCIALS
8.15.4 STRATEGY
8.15.5 DEVELOPMENTS
8.16 BIOJECT, INC.
8.16.1 OVERVIEW
8.16.2 PRODUCTS & SERVICES
8.16.3 FINANCIALS
8.16.4 STRATEGY
8.16.5 DEVELOPMENTS
8.17 ALKERMES, INC.
8.17.1 OVERVIEW
8.17.2 PRODUCTS & SERVICES
8.17.3 FINANCIALS
8.17.4 STRATEGY
8.17.5 DEVELOPMENTS
8.18 WEST PHARMA SERVICES, INC.
8.18.1 OVERVIEW
8.18.2 PRODUCTS & SERVICES
8.18.3 FINANCIALS
8.18.4 STRATEGY
8.18.5 DEVELOPMENTS
8.19 OWEN MUMFORD LTD.
8.19.1 OVERVIEW
8.19.2 PRODUCTS & SERVICES
8.19.3 FINANCIALS
8.19.4 STRATEGY
8.19.5 DEVELOPMENTS
8.2 YPSOMED HOLDING AG
8.20.1 OVERVIEW
8.20.2 PRODUCTS & SERVICES
8.20.3 FINANCIALS
8.20.4 STRATEGY
8.20.5 DEVELOPMENTS
8.21 ANTARES PHARMA, INC.
8.21.1 OVERVIEW
8.21.2 PRODUCTS & SERVICES
8.21.3 FINANCIALS
8.21.4 STRATEGY
8.21.5 DEVELOPMENTS
8.22 QLT, INC.
8.22.1 OVERVIEW
8.22.2 PRODUCTS & SERVICES
8.22.3 FINANCIALS
8.22.4 STRATEGY
8.22.5 DEVELOPMENTS
8.23 NEKTAR THERAPEUTICS, LTD.
8.23.1 OVERVIEW
8.23.2 PRODUCTS & SERVICES
8.23.3 FINANCIALS
8.23.4 STRATEGY
8.23.5 DEVELOPMENTS
LIST OF TABLES
1 GLOBAL INJECDRUG DELIVERY MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
2 MARKETED BIOLOGIC DRUGS
3 GLOBAL DRUG SALES VS. BIOLOGIC SALES, 2004 – 2015 ($BILLION)
4 GLOBAL INJECDRUG DELIVERY DEVICES MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
5 INJECDRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
6 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
7 CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
8 GLOBAL PREFILLED SYRINGES MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
9 PREFILLED SYRINGES MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
10 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
11 SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
12 GLOBAL AUTO INJECTOR MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
13 AUTO INJECTOR MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
14 GLOBAL PEN INJECTOR MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
15 PEN INJECTOR MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
16 MAJOR PRODUCTS IN THE NEEDLE FREE TECHNOLOGY
17 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
18 GLOBAL INJECDRUG DELIVERY FORMULATION MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
19 INJECDRUG DELIVERY FORMULATION MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
20 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
21 MARKETED LIPOSOMAL SYSTEM BASED DRUG PRODUCTS
22 LIPOSOMAL SYSTEMS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
23 MICROSPHERE MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
24 MARKETED MICROSPHERE DRUG PRODUCTS
25 POLYMERIC MICELLE MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
26 MARKETED POLYMERIC MICELLE BASED DRUG PRODUCTS
27 BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
28 OTHER INJECDRUG DELIVERY FORMULATION MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
29 GLOBAL INJECDRUG DELIVERY THERAPEUTICS MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
30 INJECDRUG DELIVERY THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
31 MARKETED THERAPIES FOR MULTIPLE SCLEROSIS
32 TOP FIVE MULTIPLE SCLEROSIS PRODUCTS (2009)
33 ORAL MULTIPLE SCLEROSIS THERAPIES IN CLINICAL TRIALS
34 MULTIPLE SCLEROSIS PREVALENCE, BY GEOGRAPHY (2009)
35 MULTIPLE SCLEROSIS THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
36 MARKETED THERAPIES FOR OSTEOPOROSIS
37 TOP FIVE ANTI-OSTEOPOROSIS PRODUCTS (2009)
38 OSTEOPOROSIS PREVALENCE, BY GEOGRAPHY (2009)
39 OSTEOPOROSIS THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
40 PAIN MANAGEMENT THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
41 MARKETED THERAPIES FOR DIABETES
42 TOP FIVE ANTI-DIABETES PRODUCTS (2009)
43 DIABETES PREVALENCE BY GEOGRAPHY (2009)
44 DIABETES THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
45 TOP FIVE ONCOLOGY PRODUCTS (2009)
46 CANCER PREVALENCE, BY GEOGRAPHY (2009)
47 ONCOLOGY THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
48 MARKETED THERAPIES FOR RHEUMATOID ARTHRITIS
49 TOP FIVE ANTI RHEUMATIC PRODUCTS (2009)
50 RHEUMATOID ARTHRITIS PREVALENCE, BY GEOGRAPHY (2009)
51 RHEUMATOID ARTHRITIS THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
52 TOP FIVE ANTI-ANEMIA PRODUCTS (2009)
53 ANEMIA PREVALENCE, BY GEOGRAPHY (2009)
54 ANEMIA THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
55 TOP FIVE ANTI-HEPATITIS-C PRODUCTS (2009)
56 HEPATITIS-C PREVALENCE, BY GEOGRAPHY (2009)
57 HEPATITIS-C THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
58 CROHN’S DISEASE PREVALENCE, BY GEOGRAPHY (2009)
59 CROHN’S DISEASE THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
60 TOP FIVE ANTI-PSORIASIS PRODUCTS (2009)
61 PSORIASIS THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
62 PSORIASIS PREVALENCE, BY GEOGRAPHY (2009)
63 OTHER INJECDRUG DELIVERY THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
64 AGREEMENTS & PARTNERSHIPS (2008 – 2010)
65 NEW PRODUCT LAUNCH (2008 – 2010)
66 EXPANSIONS (2008 – 2010)
67 REGULATORY APPROVALS (2008 – 2010)
68 MERGERS & ACQUISITIONS (2008 – 2010)
69 BAXTER BIOPHARMA - TOTAL REVENUES & R&D EXPENSES ($MILLION)
70 BAXTER BIOPHARMA – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
71 BAXTER BIOPHARMA - TOTAL REVENUES, BY SEGMENT ($MILLION)
72 BAXTER BIOPHARMA – TOTAL REVENUES FOR MEDICATION DELIVERY, BY SEGMENT ($MILLION)
73 BECTON DICKINSON – TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
74 BECTON DICKINSON – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
75 BECTON DICKINSON – TOTAL REVENUES BY SEGMENT ($MILLION)
76 BECTON DICKINSON – TOTAL REVENUES FOR MEDICAL SURGICAL SYSTEMS, BY SEGMENT ($MILLION)
77 SCHOTT AG – TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
78 SURMODICS, INC. – TOTAL REVENUES & R&D EXPENSES ($MILLION)
79 SURMODICS, INC. – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
80 SURMODICS, INC. – TOTAL REVENUES, BY SEGMENT ($MILLION)
81 GERRESHEIMER AG – TOTAL REVENUES & R&D EXPENSES ($MILLION)
82 GERRESHEIMER AG – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
83 B. BRAUN – TOTAL REVENUES & R&D EXPENSES ($MILLION)
84 B. BRAUN – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
85 B. BRAUN – TOTAL REVENUES, BY SEGMENT ($MILLION)
86 TERUMO CORPORATION – TOTAL REVENUES & R&D EXPENSES ($MILLION)
87 TERUMO CORPORATION – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
88 TERUMO CORPORATION – TOTAL REVENUES, BY SEGMENT ($MILLION)
89 AP PHARMA – TOTAL REVENUES & R&D EXPENSES ($MILLION)
90 BIOJECT - TOTAL REVENUES & R&D EXPENSES ($MILLION)
91 BIOJECT - TOTAL REVENUES, BY SEGMENT ($MILLION)
92 ALKERMES - TOTAL REVENUES & R&D EXPENSES ($MILLION)
93 ALKERMES – SEGMENT SPECIFIC REVENUES ($MILLION)
94 WEST PHARMA - TOTAL REVENUES & R&D EXPENSES, ($MILLION)
95 WEST PHARMA – TOTAL REVENUES, BY GEOGRAPHY, ($MILLION)
96 WEST PHARMA – TOTAL REVENUES, BY SEGMENT ($MILLION)
97 YPSOMED - TOTAL REVENUES & R&D EXPENSES ($MILLION)
98 YPSOMED - TOTAL REVENUES BY SEGMENT ($MILLION)
99 ANTARES PHARMA - TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
100 ANTARES PHARMA - TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
101 QLT – TOTAL REVENUES & R&D EXPENSES ($MILLION)
102 QLT – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
103 NEKTAR - TOTAL REVENUES & R&D EXPENSES ($MILLION)
104 NEKTAR – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
1 GLOBAL INJECDRUG DELIVERY MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
2 MARKETED BIOLOGIC DRUGS
3 GLOBAL DRUG SALES VS. BIOLOGIC SALES, 2004 – 2015 ($BILLION)
4 GLOBAL INJECDRUG DELIVERY DEVICES MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
5 INJECDRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
6 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
7 CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
8 GLOBAL PREFILLED SYRINGES MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
9 PREFILLED SYRINGES MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
10 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
11 SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
12 GLOBAL AUTO INJECTOR MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
13 AUTO INJECTOR MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
14 GLOBAL PEN INJECTOR MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
15 PEN INJECTOR MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
16 MAJOR PRODUCTS IN THE NEEDLE FREE TECHNOLOGY
17 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
18 GLOBAL INJECDRUG DELIVERY FORMULATION MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
19 INJECDRUG DELIVERY FORMULATION MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
20 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
21 MARKETED LIPOSOMAL SYSTEM BASED DRUG PRODUCTS
22 LIPOSOMAL SYSTEMS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
23 MICROSPHERE MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
24 MARKETED MICROSPHERE DRUG PRODUCTS
25 POLYMERIC MICELLE MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
26 MARKETED POLYMERIC MICELLE BASED DRUG PRODUCTS
27 BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
28 OTHER INJECDRUG DELIVERY FORMULATION MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
29 GLOBAL INJECDRUG DELIVERY THERAPEUTICS MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)
30 INJECDRUG DELIVERY THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
31 MARKETED THERAPIES FOR MULTIPLE SCLEROSIS
32 TOP FIVE MULTIPLE SCLEROSIS PRODUCTS (2009)
33 ORAL MULTIPLE SCLEROSIS THERAPIES IN CLINICAL TRIALS
34 MULTIPLE SCLEROSIS PREVALENCE, BY GEOGRAPHY (2009)
35 MULTIPLE SCLEROSIS THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
36 MARKETED THERAPIES FOR OSTEOPOROSIS
37 TOP FIVE ANTI-OSTEOPOROSIS PRODUCTS (2009)
38 OSTEOPOROSIS PREVALENCE, BY GEOGRAPHY (2009)
39 OSTEOPOROSIS THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
40 PAIN MANAGEMENT THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
41 MARKETED THERAPIES FOR DIABETES
42 TOP FIVE ANTI-DIABETES PRODUCTS (2009)
43 DIABETES PREVALENCE BY GEOGRAPHY (2009)
44 DIABETES THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
45 TOP FIVE ONCOLOGY PRODUCTS (2009)
46 CANCER PREVALENCE, BY GEOGRAPHY (2009)
47 ONCOLOGY THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
48 MARKETED THERAPIES FOR RHEUMATOID ARTHRITIS
49 TOP FIVE ANTI RHEUMATIC PRODUCTS (2009)
50 RHEUMATOID ARTHRITIS PREVALENCE, BY GEOGRAPHY (2009)
51 RHEUMATOID ARTHRITIS THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
52 TOP FIVE ANTI-ANEMIA PRODUCTS (2009)
53 ANEMIA PREVALENCE, BY GEOGRAPHY (2009)
54 ANEMIA THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
55 TOP FIVE ANTI-HEPATITIS-C PRODUCTS (2009)
56 HEPATITIS-C PREVALENCE, BY GEOGRAPHY (2009)
57 HEPATITIS-C THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
58 CROHN’S DISEASE PREVALENCE, BY GEOGRAPHY (2009)
59 CROHN’S DISEASE THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
60 TOP FIVE ANTI-PSORIASIS PRODUCTS (2009)
61 PSORIASIS THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
62 PSORIASIS PREVALENCE, BY GEOGRAPHY (2009)
63 OTHER INJECDRUG DELIVERY THERAPEUTICS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
64 AGREEMENTS & PARTNERSHIPS (2008 – 2010)
65 NEW PRODUCT LAUNCH (2008 – 2010)
66 EXPANSIONS (2008 – 2010)
67 REGULATORY APPROVALS (2008 – 2010)
68 MERGERS & ACQUISITIONS (2008 – 2010)
69 BAXTER BIOPHARMA - TOTAL REVENUES & R&D EXPENSES ($MILLION)
70 BAXTER BIOPHARMA – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
71 BAXTER BIOPHARMA - TOTAL REVENUES, BY SEGMENT ($MILLION)
72 BAXTER BIOPHARMA – TOTAL REVENUES FOR MEDICATION DELIVERY, BY SEGMENT ($MILLION)
73 BECTON DICKINSON – TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
74 BECTON DICKINSON – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
75 BECTON DICKINSON – TOTAL REVENUES BY SEGMENT ($MILLION)
76 BECTON DICKINSON – TOTAL REVENUES FOR MEDICAL SURGICAL SYSTEMS, BY SEGMENT ($MILLION)
77 SCHOTT AG – TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
78 SURMODICS, INC. – TOTAL REVENUES & R&D EXPENSES ($MILLION)
79 SURMODICS, INC. – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
80 SURMODICS, INC. – TOTAL REVENUES, BY SEGMENT ($MILLION)
81 GERRESHEIMER AG – TOTAL REVENUES & R&D EXPENSES ($MILLION)
82 GERRESHEIMER AG – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
83 B. BRAUN – TOTAL REVENUES & R&D EXPENSES ($MILLION)
84 B. BRAUN – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
85 B. BRAUN – TOTAL REVENUES, BY SEGMENT ($MILLION)
86 TERUMO CORPORATION – TOTAL REVENUES & R&D EXPENSES ($MILLION)
87 TERUMO CORPORATION – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
88 TERUMO CORPORATION – TOTAL REVENUES, BY SEGMENT ($MILLION)
89 AP PHARMA – TOTAL REVENUES & R&D EXPENSES ($MILLION)
90 BIOJECT - TOTAL REVENUES & R&D EXPENSES ($MILLION)
91 BIOJECT - TOTAL REVENUES, BY SEGMENT ($MILLION)
92 ALKERMES - TOTAL REVENUES & R&D EXPENSES ($MILLION)
93 ALKERMES – SEGMENT SPECIFIC REVENUES ($MILLION)
94 WEST PHARMA - TOTAL REVENUES & R&D EXPENSES, ($MILLION)
95 WEST PHARMA – TOTAL REVENUES, BY GEOGRAPHY, ($MILLION)
96 WEST PHARMA – TOTAL REVENUES, BY SEGMENT ($MILLION)
97 YPSOMED - TOTAL REVENUES & R&D EXPENSES ($MILLION)
98 YPSOMED - TOTAL REVENUES BY SEGMENT ($MILLION)
99 ANTARES PHARMA - TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
100 ANTARES PHARMA - TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
101 QLT – TOTAL REVENUES & R&D EXPENSES ($MILLION)
102 QLT – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
103 NEKTAR - TOTAL REVENUES & R&D EXPENSES ($MILLION)
104 NEKTAR – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
LIST OF FIGURES
1 INJECTABLE DRUG DELIVERY DEVICES MARKET (2010 – 2015)
2 INJECTABLE DRUG DELIVERY FORMULATION MARKET (2010 – 2015)
3 INJECTABLE DRUG DELIVERY DEVICES MARKET (2009)
4 DRUG DELIVERY TECHNOLOGY BY ROUTE OF ADMINISTRATION (2009)
5 GLOBAL BIOLOGIC DRUG SALES (2004 – 2015)
6 GLOBAL BIOLOGICS DRUG SALES BY ROUTE OF DRUG ADMINISTRATION (2010)
7 INJECTABLE DRUG DELIVERY DEVICES MARKET SCENARIO (2009)
8 PRODUCT LIFE CYCLE OPTIONS FOR PHARMACEUTICAL COMPANIES
9 IMPACT OF KEY MARKET DRIVERS AND RESTRAINTS
10 MARKET SHARE OF MAJOR PLAYERS
11 FACTORS AFFECTING SELECTION OF INJECTABLE DEVICE
12 SIZE OF NANOPARTICLES AND TARGET SITES FOR DRUG DELIVERY
13 DRUG DELIVERY FORMULATION MARKET SCENARIO
14 GLOBAL DRUG SALES BY ROUTE OF ADMINISTRATION (2009)
15 INDUSTRY GROWTH STRATEGIES (2008 – 2010)
1 INJECTABLE DRUG DELIVERY DEVICES MARKET (2010 – 2015)
2 INJECTABLE DRUG DELIVERY FORMULATION MARKET (2010 – 2015)
3 INJECTABLE DRUG DELIVERY DEVICES MARKET (2009)
4 DRUG DELIVERY TECHNOLOGY BY ROUTE OF ADMINISTRATION (2009)
5 GLOBAL BIOLOGIC DRUG SALES (2004 – 2015)
6 GLOBAL BIOLOGICS DRUG SALES BY ROUTE OF DRUG ADMINISTRATION (2010)
7 INJECTABLE DRUG DELIVERY DEVICES MARKET SCENARIO (2009)
8 PRODUCT LIFE CYCLE OPTIONS FOR PHARMACEUTICAL COMPANIES
9 IMPACT OF KEY MARKET DRIVERS AND RESTRAINTS
10 MARKET SHARE OF MAJOR PLAYERS
11 FACTORS AFFECTING SELECTION OF INJECTABLE DEVICE
12 SIZE OF NANOPARTICLES AND TARGET SITES FOR DRUG DELIVERY
13 DRUG DELIVERY FORMULATION MARKET SCENARIO
14 GLOBAL DRUG SALES BY ROUTE OF ADMINISTRATION (2009)
15 INDUSTRY GROWTH STRATEGIES (2008 – 2010)
